A Single-Dose Intranasal Combination Panebolavirus Vaccine

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2023 Jul 20

PMID 37469133

Authors

Delphine C Malherbe

J Brian Kimble

Caroline Atyeo

Stephanie Fischinger

Michelle Meyer

S Gabrielle Cody

Matthew Hyde

Galit Alter

Alexander Bukreyev

Affiliations

Soon will be listed here.

Abstract

Background: Ebolaviruses Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) cause severe human disease, which may be accompanied by hemorrhagic syndrome, with high case fatality rates. Monovalent vaccines do not offer cross-protection against these viruses whose endemic areas overlap. Therefore, development of a panebolavirus vaccine is a priority. As a vaccine vector, human parainfluenza virus type 3 (HPIV3) has the advantages of needle-free administration and induction of both systemic and local mucosal antibody responses in the respiratory tract.

Methods: To minimize the antivector immunity, genes encoding the HPIV3 envelope proteins F and HN were removed from the vaccine constructs, resulting in expression of only the ebolavirus envelope protein-glycoprotein. These second-generation vaccine constructs were used to develop a combination vaccine against EBOV, SUDV, and BDBV.

Results: A single intranasal vaccination of guinea pigs or ferrets with the trivalent combination vaccine elicited humoral responses to each of the targeted ebolaviruses, including binding and neutralizing antibodies, as well as Fc-mediated effector functions. This vaccine protected animals from death and disease caused by lethal challenges with EBOV, SUDV, or BDBV.

Conclusions: The combination vaccine elicited protection that was comparable to that induced by the monovalent vaccines, thus demonstrating the value of this combination trivalent vaccine.

Citing Articles

Evaluation of Vaccines and Therapeutics Against Ebolaviruses in the Domestic Ferret.

Cross R Methods Mol Biol. 2024; 2877:281-295.

PMID: 39585628 DOI: 10.1007/978-1-0716-4256-6_19.

Marburg Virus Medical Countermeasures.

Martins K, Wolfe D Methods Mol Biol. 2024; 2877:25-43.

PMID: 39585611 DOI: 10.1007/978-1-0716-4256-6_2.

Non-Ebola Filoviruses: Potential Threats to Global Health Security.

Munyeku-Bazitama Y, Edidi-Atani F, Takada A Viruses. 2024; 16(8).

PMID: 39205153 PMC: 11359311. DOI: 10.3390/v16081179.

References

Anderson K, Gibbons R, Edelman R, Eckels K, Putnak R, Innis B . Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis. 2011; 204(3):442-50. DOI: 10.1093/infdis/jir279. View

Meyer M, Yoshida A, Ramanathan P, Saphire E, Collins P, Crowe Jr J . Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. Cell Rep. 2018; 24(7):1816-1829. PMC: 6145141. DOI: 10.1016/j.celrep.2018.07.044. View

Brown T, Murphy B, Radl J, Haaijman J, Mestecky J . Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol. 1985; 22(2):259-64. PMC: 268371. DOI: 10.1128/jcm.22.2.259-264.1985. View

Geisbert T, Geisbert J, Leung A, Daddario-DiCaprio K, Hensley L, Grolla A . Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009; 83(14):7296-304. PMC: 2704787. DOI: 10.1128/JVI.00561-09. View

Cross R, Mire C, Borisevich V, Geisbert J, Fenton K, Geisbert T . The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus. J Infect Dis. 2016; 214(4):565-9. PMC: 4957446. DOI: 10.1093/infdis/jiw209. View

Bukreyev A, Rollin P, Tate M, Yang L, Zaki S, Shieh W . Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007; 81(12):6379-88. PMC: 1900097. DOI: 10.1128/JVI.00105-07. View

Meyer M, Garron T, Lubaki N, Mire C, Fenton K, Klages C . Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015; 125(8):3241-55. PMC: 4563760. DOI: 10.1172/JCI81532. View

Zou G, Kosikova M, Kim S, Kotian S, Wu W, Shen R . Comprehensive analysis of -glycans in IgG purified from ferrets with or without influenza A virus infection. J Biol Chem. 2018; 293(50):19277-19289. PMC: 6302183. DOI: 10.1074/jbc.RA118.005294. View

Yang L, Sanchez A, Ward J, Murphy B, Collins P, Bukreyev A . A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology. 2008; 377(2):255-64. PMC: 2519172. DOI: 10.1016/j.virol.2008.04.029. View

10.

Connolly B, Steele K, Davis K, Geisbert T, Kell W, Jaax N . Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999; 179 Suppl 1:S203-17. DOI: 10.1086/514305. View

11.

Jones S, Feldmann H, Stroher U, Geisbert J, Fernando L, Grolla A . Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7):786-90. DOI: 10.1038/nm1258. View

12.

Gormus B, Vessella R, Martin L, Kaplan M . Heterogeneity of human lymphocyte Fc receptors: studies using heat-aggregated and antigen-complexed IgG from human, rabbit, guinea pig, horse and goat. Comp Immunol Microbiol Infect Dis. 1982; 5(4):483-99. DOI: 10.1016/0147-9571(82)90074-1. View

13.

Bukreyev A, Yang L, Zaki S, Shieh W, Rollin P, Murphy B . A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006; 80(5):2267-79. PMC: 1395378. DOI: 10.1128/JVI.80.5.2267-2279.2006. View

14.

Plotkin S, KOPROWSKI H, STOKES Jr J . Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics. 1959; 23(6):1041-62. View

15.

Malherbe D, Domi A, Hauser M, Atyeo C, Fischinger S, Hyde M . A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection. NPJ Vaccines. 2022; 7(1):83. PMC: 9314403. DOI: 10.1038/s41541-022-00512-x. View

16.

Wong G, He S, Wei H, Kroeker A, Audet J, Leung A . Development and Characterization of a Guinea Pig-Adapted Sudan Virus. J Virol. 2015; 90(1):392-9. PMC: 4702555. DOI: 10.1128/JVI.02331-15. View

17.

Burlington D, Clements M, MEIKLEJOHN G, Phelan M, Murphy B . Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect Immun. 1983; 41(2):540-5. PMC: 264675. DOI: 10.1128/iai.41.2.540-545.1983. View

18.

Towner J, Sealy T, Khristova M, Albarino C, Conlan S, Reeder S . Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008; 4(11):e1000212. PMC: 2581435. DOI: 10.1371/journal.ppat.1000212. View

19.

Towner J, Paragas J, Dover J, Gupta M, Goldsmith C, Huggins J . Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology. 2005; 332(1):20-7. DOI: 10.1016/j.virol.2004.10.048. View

20.

Wong J, Layton D, Wheatley A, Kent S . Improving immunological insights into the ferret model of human viral infectious disease. Influenza Other Respir Viruses. 2019; 13(6):535-546. PMC: 6800307. DOI: 10.1111/irv.12687. View